All In Biotech

Drug Trial Radar · NCT06175767

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 2027

Primary completion

Jan 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Mthera Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease. Primary objective of the study is to evaluate the safety and tolerability of MT101-5 400 mg and 600 mg oral tablet total daily dose compared to Placebo in subjects with Parkinson's Disease.

Conditions

  • Parkinson's Disease

Interventions

  • MT101-5Drug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Change from baseline to week 12 after the first study drug administration
  2. Incidence of withdrawals due to Adverse Events (AEs)Time frame: Change from baseline to week 12 after the first study drug administration
  3. Incidence of serious adverse events (SAEs)Time frame: Change from baseline to week 12 after the first study drug administration
  4. Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Change from baseline to week 12 after the first study drug administration
  5. Change of blood pressure (both systolic and diastolic blood pressures)Time frame: Change from baseline to week 12 after the first study drug administration
  6. Change of body temperatureTime frame: Change from baseline to week 12 after the first study drug administration
  7. Change of respiratory rateTime frame: Change from baseline to week 12 after the first study drug administration
  8. ECG ventricular rate (beats per minute)Time frame: Change from baseline to week 12 after the first study drug administration
  9. ECG PR interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
  10. ECG QRS interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
  11. ECG QT interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
  12. ECG QTc interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.